Table 4 Cost effectiveness

From: The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer

 

Clinically low

Clinically high

Total

MammaPrint

Low

36

21 (wherefrom 10 × change to ER, and 11 × noncompliant towards MP)

57

High

8 (wherefrom 4 × change to CHT, and 4 × noncompliant towards MP)

10

18

Total

44

31

75

Results

 

Costs

QALYs

Incremental costs

Incremental QALYs

ICER costs/QALY

MammaPrint

€31 696

11.97

−€3779

0.73

Dominanta

Clinically

€35 475

11.24

   
  1. Abbreviations: CHT=chemotherapy; ER=oestrogen receptor; ICER=incremental cost-effectiveness ratio; MP=MammaPrint; QALY=quality-adjusted life years.
  2. aDominant: the MP is less costly and more effective compared with the clinical strategy.
Back to article page